Gadolinium-based contrast media does not improve the staging of neuroblastoma image-defined risk factors at diagnosis.

Contrast does not improve tumor size measurement or radiologist agreement on the presence or absence of IDRFs or metastatic disease in children with newly diagnosed neuroblastoma.